CBS 2019
CBSMD教育中心
中 文

充血性心力衰竭

Abstract

Recommended Article

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease Nitrosative stress drives heart failure with preserved ejection fraction Myofibroblast Phenotype and Reversibility of Fibrosis in Patients With End-Stage Heart Failure The year in cardiovascular medicine 2020: heart failure and cardiomyopathies How to diagnose heart failure with preserved ejection fraction: the HFA–PEFF diagnostic algorithm: a consensus recommendation from the Heart Failure Association (HFA) of the European Society of Cardiology (ESC) Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes H2FPEF Score for Predicting Future Heart Failure in Stable Outpatients With Cardiovascular Risk Factors Efficacy of Ertugliflozin on Heart Failure–Related Events in Patients With Type 2 Diabetes Mellitus and Established Atherosclerotic Cardiovascular Disease Results of the VERTIS CV Trial

Original Research2021 Jan 12;S0828-282X(21)00005-2.

JOURNAL:Can J Cardiol. Article Link

When and how to use SGLT2 inhibitors in patients with HFrEF or chronic kidney disease

E O'Meara, S Verma. Keywords: SGLT2 inhibitors; heart failure; chronic kidney disease

Full Text PDF